C
Calithera Biosciences Inc
F:2CB
Calithera Biosciences Inc
F:2CB
Price:
3.86
EUR
-2.53%
Market Closed
Market Cap:
€1m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
C
|
Calithera Biosciences Inc
F:2CB
|
US |
|
U
|
Uranium Energy Corp
AMEX:UEC
|
US |
|
B
|
Bin Ulasim ve Akilli Sehir Teknolojileri AS
IST:BINBN.E
|
TR |
|
PYC Therapeutics Ltd
ASX:PYC
|
AU |
|
Super Retail Group Ltd
ASX:SUL
|
AU |
|
Rosseti Kuban' PAO
MOEX:KUBE
|
RU |
|
Trade Desk Inc
NASDAQ:TTD
|
US |
|
Femasys Inc
NASDAQ:FEMY
|
US |
|
A
|
AprilBio Co Ltd
KOSDAQ:397030
|
KR |
|
Endurance Motive SA
MAD:END
|
ES |
|
D
|
Demco PCL
SET:DEMCO
|
TH |
|
Tempo Australia Ltd
ASX:TPP
|
AU |
|
First National Energy Corp
OTC:FNEC
|
CA |
|
I
|
Interarch Building Products Ltd
NSE:INTERARCH
|
IN |
|
Palladium One Mining Inc
XTSX:PDM
|
CA |
|
Vecima Networks Inc
TSX:VCM
|
CA |
Multiples-Based Value
There is not enough data to reliably calculate the multiples-based value of 2CB.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
2CB
Multiples-Based Value
Base Case
Not Available
Multiples Across Competitors
2CB Competitors Multiples
Calithera Biosciences Inc Competitors
Calithera Biosciences Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
C
|
Calithera Biosciences Inc
F:2CB
|
1m EUR | 0 | -0.1 | 0.6 | 0.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
370.2B USD | 6.1 | 88.4 | 14.7 | 20.4 | |
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
355.4B USD | 109.4 | -1 708.3 | 15 870 | -1 791.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188B USD | 5.1 | 24.4 | 14.1 | 14.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
166.6B USD | 5.7 | 19.6 | 12.3 | 15.1 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110B USD | 9.2 | 27.8 | 20.9 | 21.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78B USD | 5.4 | 17.3 | 12.7 | 14.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
69B AUD | 3.2 | 35.1 | 11.5 | 14.5 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
